HUE046702T2 - Eljárások üvegcsontbetegség kezelésére - Google Patents

Eljárások üvegcsontbetegség kezelésére

Info

Publication number
HUE046702T2
HUE046702T2 HUE17206987A HUE17206987A HUE046702T2 HU E046702 T2 HUE046702 T2 HU E046702T2 HU E17206987 A HUE17206987 A HU E17206987A HU E17206987 A HUE17206987 A HU E17206987A HU E046702 T2 HUE046702 T2 HU E046702T2
Authority
HU
Hungary
Prior art keywords
methods
osteogenesis imperfecta
treating osteogenesis
treating
imperfecta
Prior art date
Application number
HUE17206987A
Other languages
English (en)
Inventor
Brendan Lee
Kuber Sampath
Original Assignee
Genzyme Corp
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50483613&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE046702(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Baylor College Medicine filed Critical Genzyme Corp
Publication of HUE046702T2 publication Critical patent/HUE046702T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE17206987A 2013-03-20 2014-03-20 Eljárások üvegcsontbetegség kezelésére HUE046702T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803647P 2013-03-20 2013-03-20
US201361875399P 2013-09-09 2013-09-09
US201361883151P 2013-09-26 2013-09-26

Publications (1)

Publication Number Publication Date
HUE046702T2 true HUE046702T2 (hu) 2020-03-30

Family

ID=50483613

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17206987A HUE046702T2 (hu) 2013-03-20 2014-03-20 Eljárások üvegcsontbetegség kezelésére

Country Status (27)

Country Link
US (4) US9598486B2 (hu)
EP (3) EP2976359B2 (hu)
JP (3) JP6483086B2 (hu)
KR (1) KR102257138B1 (hu)
CN (2) CN111000997A (hu)
AU (1) AU2014235933B2 (hu)
CA (1) CA2907422C (hu)
CL (1) CL2015002801A1 (hu)
DK (2) DK2976359T4 (hu)
EA (1) EA032327B1 (hu)
ES (2) ES2763869T3 (hu)
HK (2) HK1213576A1 (hu)
HR (2) HRP20181939T4 (hu)
HU (1) HUE046702T2 (hu)
IL (2) IL241461B (hu)
LT (2) LT3312195T (hu)
MX (2) MX369360B (hu)
MY (1) MY172324A (hu)
PH (2) PH12015501864B1 (hu)
PL (2) PL2976359T5 (hu)
PT (2) PT2976359T (hu)
RS (2) RS59673B1 (hu)
SG (2) SG10201701985YA (hu)
SI (2) SI3312195T1 (hu)
TW (1) TWI629995B (hu)
UY (1) UY35493A (hu)
WO (1) WO2014153435A1 (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3312195T1 (sl) * 2013-03-20 2020-02-28 Genzyme Corporation Postopki zdravljenja osteogeneze imperfecta
CA3033614A1 (en) * 2016-08-11 2018-02-15 Precithera, Inc. Tgf-.beta. antagonist conjugates
CN106755395B (zh) * 2016-12-16 2020-05-12 山东第一医科大学(山东省医学科学院) Xi型成骨不全致病基因fkbp10的突变位点及其应用
AR110904A1 (es) * 2017-01-20 2019-05-15 Sanofi Sa ANTICUERPOS ANTI-TGF-b Y SU USO
WO2018134681A1 (en) * 2017-01-20 2018-07-26 Sanofi Anti-tgf-beta antibodies and their use
TWI787230B (zh) * 2017-01-20 2022-12-21 法商賽諾菲公司 抗TGF-β抗體及其用途
TWI788321B (zh) * 2017-01-20 2023-01-01 美商健臻公司 骨靶向抗體
US20190248881A1 (en) * 2017-12-04 2019-08-15 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
AU2019301283A1 (en) 2018-07-10 2021-02-04 Sanofi Combination therapies against cancer targeting CD38 and TGF-beta
CA3196077A1 (en) * 2020-10-23 2022-04-28 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
CN117730095A (zh) * 2021-05-07 2024-03-19 贝勒医学院 中度至重度成骨不全症的治疗
CN113501879B (zh) * 2021-06-30 2022-09-06 拜盖特生物科技(上海)有限公司 一种解除肿瘤免疫微环境中免疫抑制的双功能抗体及其应用和制备方法
MX2024005344A (es) * 2021-11-01 2024-07-19 Genzyme Corp Tratamiento de la osteogenesis imperfecta.
WO2024149381A1 (en) * 2023-01-13 2024-07-18 Shanghai Kaijin Biotechnology, Ltd Multi-specific polypeptide complexes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6716836A (hu) * 1967-12-11 1969-06-13
US7368111B2 (en) * 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
JP4813660B2 (ja) * 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2007076391A1 (en) 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
WO2008022182A1 (en) * 2006-08-16 2008-02-21 The Uab Research Foundation Methods for promoting coupling between bone formation and resorption
KR20180083967A (ko) * 2007-02-09 2018-07-23 악셀레론 파마 인코포레이티드 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
EP2142924A2 (en) * 2007-04-26 2010-01-13 President And Fellows Of Harvard College Assays for the identification of compounds that modulate bone formation and mineralization
AR068767A1 (es) * 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2009206082A1 (en) * 2008-01-15 2009-07-23 Kalobios Pharmaceuticals, Inc. Methods of treating bone-loss disorders using a GM-CSF antagonist
ES2702049T3 (es) * 2009-04-24 2019-02-27 Univ Vanderbilt Inducción anti-TGF-beta de crecimiento óseo
SI3312195T1 (sl) * 2013-03-20 2020-02-28 Genzyme Corporation Postopki zdravljenja osteogeneze imperfecta

Also Published As

Publication number Publication date
JP2019089826A (ja) 2019-06-13
EP3312195B1 (en) 2019-10-09
CN105229028B (zh) 2019-11-08
JP2020109110A (ja) 2020-07-16
HRP20181939T4 (hr) 2022-05-13
UY35493A (es) 2014-11-28
MX369360B (es) 2019-11-06
PL2976359T5 (pl) 2022-07-18
DK2976359T4 (da) 2022-06-13
AU2014235933B2 (en) 2019-01-24
MX2019009122A (es) 2019-09-16
KR102257138B1 (ko) 2021-05-26
JP2016519093A (ja) 2016-06-30
EP2976359A1 (en) 2016-01-27
TWI629995B (zh) 2018-07-21
SI3312195T1 (sl) 2020-02-28
PH12015501864A1 (en) 2015-12-07
HK1253717A1 (zh) 2019-06-28
US9598486B2 (en) 2017-03-21
IL241461B (en) 2021-12-01
SI2976359T2 (sl) 2022-05-31
EA201591843A1 (ru) 2016-01-29
RS58188B2 (sr) 2022-06-30
RS58188B1 (sr) 2019-03-29
ES2763869T3 (es) 2020-06-01
KR20150132262A (ko) 2015-11-25
EP2976359B2 (en) 2022-03-23
CA2907422C (en) 2021-08-31
PL2976359T3 (pl) 2019-03-29
EA032327B1 (ru) 2019-05-31
SG11201506683XA (en) 2015-09-29
CA2907422A1 (en) 2014-09-25
PH12015501864B1 (en) 2015-12-07
CN111000997A (zh) 2020-04-14
EP3640260A1 (en) 2020-04-22
LT2976359T (lt) 2018-12-27
US20170247439A1 (en) 2017-08-31
SG10201701985YA (en) 2017-04-27
EP2976359B1 (en) 2018-08-29
BR112015023905A2 (pt) 2017-10-24
JP6677837B2 (ja) 2020-04-08
RS59673B1 (sr) 2020-01-31
SI2976359T1 (sl) 2019-03-29
PL3312195T3 (pl) 2020-04-30
ES2700238T3 (es) 2019-02-14
IL287915A (en) 2022-01-01
PH12019500261B1 (en) 2020-07-20
US20220195025A1 (en) 2022-06-23
US20190389943A1 (en) 2019-12-26
IL241461A0 (en) 2015-11-30
EP3312195A1 (en) 2018-04-25
HRP20181939T1 (hr) 2019-01-25
US20160031979A1 (en) 2016-02-04
PT2976359T (pt) 2018-12-05
MY172324A (en) 2019-11-21
DK2976359T3 (da) 2019-01-02
MX2015013402A (es) 2016-01-08
ES2700238T5 (es) 2022-05-20
JP7016113B2 (ja) 2022-02-04
CN105229028A (zh) 2016-01-06
US10377819B2 (en) 2019-08-13
US11230595B2 (en) 2022-01-25
LT3312195T (lt) 2020-01-10
NZ712353A (en) 2021-04-30
CL2015002801A1 (es) 2016-08-12
DK3312195T3 (da) 2020-01-06
WO2014153435A1 (en) 2014-09-25
JP6483086B2 (ja) 2019-03-13
TW201524515A (zh) 2015-07-01
PH12019500261A1 (en) 2020-07-20
HRP20192277T1 (hr) 2020-03-06
AU2014235933A1 (en) 2015-10-01
HK1213576A1 (zh) 2016-07-08
PT3312195T (pt) 2019-12-23

Similar Documents

Publication Publication Date Title
IL287915A (en) Methods for treating brittle bones
IL240713A0 (en) Complexes for handling materials
PL2983787T3 (pl) Sposób leczenia zespołu stresu pourazowego
GB201307442D0 (en) Process Apparatus
HK1220155A1 (zh) 治療癌症的方法
GB201318983D0 (en) Radiotherapy apparatus
AP2015008803A0 (en) Methods for treating psoriasis using an anti-il-23antibody
HK1215164A1 (zh) 處理方法
HUE042470T2 (hu) Eljárás széntartalmú anyagok kezelésére gõz termolízissel
IL245541A0 (en) New methods for the treatment of neurodegenerative diseases
ZA201604486B (en) Timber treatment process
PL3016682T3 (pl) Sposoby leczenia nowotworu
EP2941270A4 (en) METHODS FOR TREATING INFLAMMATION
TWI563128B (en) Methods for treating aluminum surfaces
GB201302035D0 (en) UV Apparatus
EP3082251A4 (en) MOTOR DRIVE DEVICE
GB201322174D0 (en) Process for treating steel components
ZA201506163B (en) Methods for treating osteogenesis imperfecta
GB201322764D0 (en) Treating places
EP2838532A4 (en) PROCESS FOR TREATING SCLERRODERY